The invention provides compositions and methods utilizing low concentrations of selective alpha-2 adrenergic receptor agonists, preferably, brimonidine. The invention provides contact lens solutions and methods of using these solutions for pre-soaking contact lenses to achieve reduction of redness and/or increase in whitening of eyes. The invention also provides compositions including a selective alpha-2 adrenergic receptor agonist in a combination with an ocular medical device, including but no...

An alpha2 adrenoreceptor agonist eg. clonidine brimonidine monoxidine lofexidine is useful for the treatment of siaiorrhoea administered by the paraungual sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin glycopyrrolate ipratropium.

The present invention is directed to compositions comprising combinations of brimonidine and bimatoprost useful for lowering intraocular pressure in a patient and for the treatment of glaucoma.

The invention provides compositions and methods for whitening of eyes and/or reducing redness of eyes. The provided compositions and methods utilize low concentrations of selective alpha-2 adrenergic receptor agonists. The compositions preferably include brimonidine, dexmedetomidine, guanfacine or fadolmidine.

The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective alpha-2 adrenergic receptor agonists. The compositions preferably include brimonidine.

The invention provides compositions and methods for treating nasal congestion. The provided compositions and methods utilize low concentrations of selective alpha-2 adrenergic receptor agonists. The compositions preferably include brimonidine.

Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

ABSTRACT - 599669 The disclosure relates to a therapeutically effective aqueous ophthalmic composition comprising a solubility enhancing component (SEC) selected from the group consisting of povidone, polyvinyl alcohol and sodium carboxymethyl cellulose, a preservative selected from the group consisting of a quaternary ammonium preservative, an oxidative preservative, and a biguanide preservative, and 0.1% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline tartrate (brimonidine tartrate), w...

Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.